

PUBLISHED SCIENTIFIC EVIDENCE OF PROMONITOR IN PEER-REVIEWED JOURNALS

UPDATED THROUGH JANUARY 2024

Peer-reviewed articles have been classified as follows:

LAB COMPARISONS	2
POINT-OF-CARE TESTS	5
GASTROENTEROLOGY	6
RHEUMATOLOGY	10
DERMATOLOGY	14
OPHTHALMOLOGY	15
COST-EFFECTIVENESS	16
IMMUNOGENICITY	17
GENETICS	18
WHO INTERNATIONAL STANDARDS	19

GRIFOLS

LAB COMPARISONS

1. Rissel F, Cazaubon Y, Saffar S, Altwegg R, Artasone M, Lozano C, Vincent T, Jentzer A. **Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.** *Int J Mol Sci.* 2023;24(12):10379. PMID: [37373525](#).
2. Cheli S, Savino D, Penagini F, Zuccotti G, Zuin G, Clementi E, Cattaneo D. **Therapeutic Drug Monitoring of Anti-TNF α Inhibitors: A Matter of Cut-Off Ranges.** *Pharmaceutics.* 2023;15(7):1834. PMID: [37514022](#).
3. Vande Castele N, Yang L, Dobler I, Agboton C, McRorie Osborn T, Suri A, Lindner D, Smithson GM. **Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay.** *Ther Drug Monit.* 2023;45(2):236-244. PMID: [36788448](#).
4. Laserna-Mendieta EJ, Salvador-Martín S, Marín-Jiménez I, Menchén LA, López-Cauce B, López-Fernández LA, Lucendo AJ. **Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.** *J Pharm Biomed Anal.* 2021;198:114003. PMID: [33714800](#).
5. Villemonteix J, Guérin-El Khourouj V, Hugot JP, Giardini C, Carcelain G, Martinez-Vinson C. **Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.** *Biologicals.* 2021;70:17-21. PMID: [33676831](#).
6. West TA, Sam M, Toong C. **Comparison of three commercially available ELISA assays for anti-infliximab antibodies.** *Pathology.* 2021;53(4):508-514. PMID: [33272693](#).
7. Sam MJ, Connor SJ, Ng WW, Toong CM. **Comparative evaluation of 4 commercially available ELISA kits for measuring adalimumab and antiadalimumab antibodies.** *Ther Drug Monit.* 2020;42(6):821-828. PMID: [32947553](#).
8. Neveu B, Kunst A, Prosser C, Robitaille R. **An in vitro comparison of four different immunoassays for the monitoring of infliximab biosimilars drug levels.** *Clin Biochem.* 2020;78:58-62. PMID: [31982376](#).
9. Verdon C, Vande Castele N, Heron V, Germain P, Afif W. **Comparison of serum concentrations of ustekinumab obtained by three commercial assays in patients with Crohn's disease.** *J Can Assoc Gastroenterol.* 2020;4(2):73-77. PMID: [33855264](#).
10. Bertin D, Serrero M, Grimaud JC, Desjeux A, Desplat-Jégo S. **Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.** *Cytokine.* 2020;126:154859. PMID: [31629989](#).
11. Novakovic V, Abdija S, Larsen PB, Fenger M, Gredal L, Jacobsen KK. **Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of infliximab levels.** *Clin Biochem.* 2019;74:73-75. PMID: [31669514](#).
12. Laserna-Mendieta EJ, Salvador-Martín S, Arias-González L, Ruiz-Ponce M, Menchén LA, Sánchez C, López-Fernández LA, Lucendo AJ. **Comparison of a new rapid method for the determination of adali-**

mumab serum levels with two established ELISA kits. Clin Chem Lab Med. 2019;57(12):1906-1914. PMID: [31085742](#).

13. Curci D, Lucafo M, Cifu A, Bramuzzo M, Martellosi S, Favretto D, De Pellegrin F, Fabris M, Vascotto F, Naviglio S, Ventura A, Stocco G, Decorti G. **Determination of serum infliximab concentration by point-of-care devices in children with inflammatory bowel disease.** J Pediatr Gastroenterol Nutr. 2019;69(4):474-479. PMID: [31149938](#).
14. Charfi R, Mahmoud I, Ben Salem F, Moalla M, Bouden S, Sfar I, Saïdane O, Klouz A, Daghfous R, Gorgi Y, Abdelmoula L, Trabelsi S. **Comparaison de deux réactifs de dosage plasmatique des anticorps anti-infliximab [Comparison of two kits of anti-infliximab antibodies plasmatic measurement].** Ann Biol Clin (Paris). 2019;77(4):453-458. Article in French. PMID: [31418707](#).
15. Langford T, Arkir Z, Chalkidou A, Goddard K, Kaftantzi L, Samaan M, Irving P. **The clinical and cost-effectiveness of 4 enzymelinked immunosorbent assay kits for monitoring infliximab in Crohn disease patients: protocol for a validation study.** JMIR Res Protoc. 2018;7(10):e11218. PMID: [30341052](#).
16. Pérez I, Fernández L, Sánchez-Ramón S, Alba C, Zatarain A, Cañas M, López ON, Olivares D, Rey E, Taxonera C. **Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels.** Therap Adv Gastroenterol. 2018;11:1756284818783613. PMID: [30034528](#).
17. Nasser Y, Labetoulle R, Harzallah I, Berger AE, Roblin X, Paul S. **Comparison of point-of-care and classical immunoassays for the monitoring infliximab and antibodies against infliximab in IBD.** Dig Dis Sci. 2018;63(10):2714-2721. PMID: [29948562](#).
18. Bader LI, Solberg SM, Kaada SH, Bolstad N, Warren DJ, Gavasso S, Gjesdal CG, Vedeler CA. **Assays for infliximab drug levels and antibodies: a matter of scales and categories.** Scand J Immunol. 2017;86(3):165-170. PMID: [28561325](#).
19. Nagore D, Rapún N, Antón I, Harper J, Martínez A. Response to: **Comparison of infliximab drug measurement across three commercially available ELISA kits.** Pathology. 2017;49(3):332-334. PMID: [28274669](#).
20. Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A. **Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.** Rheumatology (Oxford). 2016;55(11):2050-2055. PMID: [27565176](#).
21. Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, Scharnhorst V, Broeren MA. **Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.** Clin Chem Lab Med. 2016;54(7):1211-1219. PMID: [26587745](#).
22. Valor L, Hernández-Flórez D, de la Torre I, Llinares F, Rosas J, Yagüe J, Garrido J, Naredo E. **Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and inter-assay comparison.** Clin Exp Rheumatol. 2015;33(5):617-623. PMID: [26316061](#).
23. Fabris M, Pistis C, Zabotti A, Picco L, Curcio F, Tonutti E, De Vita S. **The detection of anti-adalimumab antibodies in a series of inflammatory polyarthritis: three ELISA methods compared.** Drug Metab Lett. 2015;9(2):132-137. PMID: [26256298](#).
24. Llinares-Tello F, Rosas-Gómez de Salazar J, Senabre-Gallego JM, Santos-Soler G, Santos-Ramírez C, Salas-Heredia E, Barber-Vallés X, Molina-García J; AIRE-MB Group. **Practical application of acid dissociation**

in monitoring patients treated with adalimumab. Rheumatol Int. 2014;34(12):1701-1708. Erratum in: Rheumatol Int. 2014;34(12):1709. PMID: [24816715](#).

25. Llinares-Tello F, Rosas J, de la Torre I, Valor L, Barber X, Senabre JM; el Grupo AIRE-MB, HUGM. **Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis.** Reumatol Clin. 2014;10(2):105-108. Article in English, Spanish. PMID: [24035361](#).
26. Ruiz-Argüello B, del Agua AR, Torres N, Monasterio A, Martínez A, Nagore D. **Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels.** Clin Chem Lab Med. 2013;51(12):e287-289. PMID: [23917475](#).
27. Llinares-Tello F, de Salazar JR, Gallego JM, Soler GS, Ramírez CS, Heredia ES, García JM. **Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab.** Clin Chem Lab Med. 2012;50(10):1845-1847. PMID: [23089717](#).

POINT-OF-CARE TESTS

1. Valdés-Delgado T, Aguado-Paredes A, Merino-Bohórquez V, Martín-Manzanares J, Alonso MM, Maldonado B, Castro L, Belvis M, Benítez B, Caunedo Á, Calleja MÁ, Argüelles-Arias F. **Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.** Dig Dis Sci. 2024;69(1):228-234. PMID: [37943382](#).
2. Facchin S, Buda A, Cardin R, Agbariah N, Zingone F, De Bona M, Zaetta D, Bertani L, Ghisa M, Barberio B, Savarino EV. **Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients.** Therap Adv Gastroenterol. 2021;14:1756284821999902. PMID: [33815569](#).

GASTROENTEROLOGY

1. Baraúna FSB, Magro DO, Miranda EF, Marçal GN, Nones RB, Kotze PG. **Correlation between trough levels of infliximab and postoperative endoscopic recurrence in Crohn's disease patients submitted to ileocolonic resections.** Eur J Gastroenterol Hepatol. 2024;36(1):33-38. PMID: [37823439](#).
2. Toja-Camba FJ, García-Quintanilla L, Rodríguez-Martinez L, Tomine J, Cajade-Pascual F, Feitosa C, Zarra-Ferro I, Barreiro-De-Acosta M, González-López J, Mondelo-García C, Fernández-Ferreiro A. **Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA.** Pharmaceutics. 2023;15(11):2615. PMID: [38004593](#).
3. Papamichael K, Stocco G, Ruiz Del Agua A. **Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.** Ther Drug Monit. 2023;45(5):579-590. PMID: [37012629](#).
4. Argüelles-Arias F, Valdés Delgado T, Maldonado Pérez B, González Antuña J, Castro Laria L. **Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.** Therap Adv Gastroenterol. 2023;16:17562848231191670. PMID: [37655058](#).
5. Lelong M, Josien R, Coste-Burel M, Rimbart M, Bressollette-Bodin C, Nancey S, et al. **The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics.** Front Immunol. 2023;14:1243898. PMID: [37701431](#).
6. Gianolio L, Armstrong K, Swann E, Shepherd R, Henderson P, Wilson DC, Russell RK. **Effectiveness of Switching to Subcutaneous Infliximab in Pediatric Inflammatory Bowel Disease Patients on Intravenous Maintenance Therapy.** J Pediatr Gastroenterol Nutr. 2023;77(2):235-239. PMID: [37219971](#).
7. Kappelman MD, Wohl DA, Herfarth HH, Firestine AM, Adler J, Ammourey RF et al. **Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial.** Gastroenterology. 2023;165(1):149-161. e7. PMID: [37004887](#).
8. Serrano-Díaz L, Iniesta-Navalón C, Gómez-Espín R, Nicolás-de Prado I, Bernal-Morell E, Rentero-Redondo L. **Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach.** Rev Esp Enferm Dig. 2023;115(8):435-443. PMID: [36562529](#).
9. Díaz LS, Navalón CI, Espín RG, Prado IN, Redondo LR. **Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease.** Gastroenterol Hepatol. 2023 ;46(7):504-511. English, Spanish. PMID: [36400260](#).
10. Diz-Lois Palomares M^aT, Porta Sánchez Á, Elberdin Pazos L, González Conde B, Outeda Macías M, Vázquez Rey MT, Estévez Prieto E, Martín Herranz I, Alonso Aguirre P. **Pharmacokinetic and clinical monitoring through posologic changes in adalimumab intensification regimen from 40 mg every week to 80 mg every other week.** Rev Esp Enferm Dig. 2022;114(12):708-712. PMID: [35170328](#).
11. Rodríguez Azor B, Martín-Masot R, Dayaldasani Khialani A, Fernández-Martín JM, Gallego Fernández C, Navas-López VM. **La monitorización proactiva de niveles de anti-TNF mejora el seguimiento de los**

pacientes pediátricos con enfermedad de Crohn [Proactive monitoring of anti-TNF agents improves followup of paediatric patients with Crohn disease]. *Anales de Pediatría.* <https://doi.org/10.1016/j.an-pedi.2022.05.012>.

12. Eberl A, Qadri S, Saavalainen P, Sipponen T. **Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.** *Eur J Gastroenterol Hepatol.* 2022;34(11):1125-1131. PMID: [36170681](#).
13. Huguet JM, García-Lorenzo V, Martí L, Paredes JM, Ramírez JJ, Pastor M, Ruiz L, Sanahuja A, Timoneda P, Sanchís L, Pérez GA, Boscá-Watts MM. **Subcutaneous infliximab [CT-P13], a True Biologic 2.0. Real clinical practice multicentre study.** *Biomedicines.* 2022;10(9):2130. PMID: [36140230](#).
14. Vaughan R, Murphy E, Nalder M, Gibson RN, Ardalan Z, Boussioutas A, Christensen B. **Infliximab trough levels are associated with transmural sonographic healing in inflammatory bowel disease.** *Inflamm Bowel Dis.* 2023;29(7):1080-1088. PMID: [36094156](#).
15. Gu B, Venkatesh K, Williams AJ, Ng W, Corte C, Gholamrezaei A, Ghaly S, Xuan W, Paramsothy S, Connor S. **Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease.** *World J Gastroenterol.* 2022;28(23):2597-2608. PMID: [35949350](#).
16. De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M, Begun J, Borok N, Brown DJM, Cheung W, Connor SJ, Gerstenmaier J, Gilbert LE, Gilmore R, Gu B, Kutaiba N, Lee A, Mahy G, Srinivasan A, Thin L, Thompson AJ, Welman CJ, Yong EXZ, De Cruz P, van Langenberg D, Sparrow MP, Ding NS. **Higher anti-tumor necrosis factor- α levels correlate with improved radiologic outcomes in Crohn's perianal fistulas.** *Clin Gastroenterol Hepatol.* 2022;20(6):1306-1314. PMID: [34389484](#).
17. Massimi D, Barberio B, Bertani L, Costa F, Ferronato A, Facchin S, Cardin R, Cingolani L, Casadei C, D'Inca R, Zingone F, Savarino EV. **Switching from infliximab originator to SB2 biosimilar in inflammatory bowel diseases: a multicentric prospective real-life study.** *Therap Adv Gastroenterol.* 2021;14:17562848211023384. PMID: [34249147](#).
18. Lucafò M, Curci D, Bramuzzo M, Alvisi P, Martelossi S, Silvestri T, Guastalla V, Labriola F, Stocco G, Decorti G. **Serum adalimumab levels after induction are associated with long-term remission in children with inflammatory bowel disease.** *Front Pediatr.* 2021;9:646671. PMID: [34017806](#).
19. Trystram N, Abitbol V, Tannoury J, Lecomte M, Assaraf J, Malamut G, Gagnière C, Barré A, Sobhan Ii, Chaussade S, Amiot A. **Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.** *Aliment Pharmacol Ther.* 2021;53(8):887-899. PMID: [33647174](#)
20. Iniesta-Navalón C, Gil-Candel M, Salar-Valverde I, Nicolás-De Prado I, Gómez-Espín R, Rentero-Redondo L. **Biosimilar infliximab CPT-13 in inflammatory bowel disease in real clinical setting: pharmacokinetics outcomes, immunogenicity and drug survival.** *Rev Esp Enferm Dig.* 2021;113(11):770-775. PMID: [33486961](#).
21. Ward MG, Rosella O, Rosella G, Martin C, Gibson PR. **Comparison of SB2-infliximab with originator-infliximab in the measurement of serum concentrations a short communication.** *Ther Drug Monit.* 2021;43(5):692-695. PMID: [33492105](#).
22. Fischer S, Cohnen S, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, Zundler S, Rath T, Krebs S, Dörje F, Uter W, Nagore D, Meyer S, Neurath MF, Atreya R. **Long-term effectiveness, safety and immu-**

nogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therap Adv Gastroenterol. 2021;14:1756284820982802. PMID: [33505519](#).

23. Ganzleben I, Geppert C, Osaba L, Hirschmann S, Nägel A, Glück C, Hoffman A, Rath T, Nagore D, Neurath MF, Atreya R. **Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis.** Therap Adv Gastroenterol. 2020;13:1756284820954112. PMID: [33101457](#).
24. Valdés Delgado T, Guerra Veloz MF, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bo-hórquez V, Sáez A, Caunedo Álvarez Á, Argüelles Arias F. **Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice.** Rev Esp Enferm Dig. 2020;112(10):756-761. PMID: [32954770](#).
25. Martín-Gutiérrez N, Sánchez-Hernández JG, Rebollo N, Pordomingo AF, Muñoz F, Otero MJ. **Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.** Eur J Hosp Pharm. 2020;ejh-pharm-2020-002410. PMID: [33115797](#).
26. Syed N, Tolaymat M, Brown SA, Sivasailam B, Cross RK. **Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab treatment and lower healthcare utilization compared with reactive and clinical monitoring.** Crohns Colitis 360. 2020;2(3):otaa050. PMID: [32743546](#).
27. Gil Candel M, Gascón Cánovas JJ, Urbietta Sanz E, Gómez Espín R, Nicolás de Prado I, Iniesta Navalón C. **Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease.** Rev Esp Enferm Dig. 2020;112(5):360-366. PMID: [32338010](#).
28. Ganzleben I, Hirschmann S, Köhler J, Fuchs FS, Rieker RJ, Baer E, Klenske E, Nagore D, Neurath MF, Atreya R. **Successful therapy of Crohn's disease-associated pulmonary necrobiotic nodules on ustekinumab therapy.** Am J Gastroenterol. 2020;115(4):632-634. PMID: [32149778](#).
29. Sánchez-Hernández JG, Rebollo N, Martín-Suarez A, Calvo MV, Muñoz F. **A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease.** Br J Clin Pharmacol. 2020;86(6):1165-1175. PMID: [32022291](#).
30. Gil-Candel M, Gascón-Cánovas JJ, Urbietta-Sanz E, Rentero-Redondo L, Onteniente-Candela M, Iniesta-Navalón C. **Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.** Int J Clin Pharm. 2020;42(2):500-507. PMID: [32006141](#).
31. Santacana E, Rodríguez-Alonso L, Padullés A, Guardiola J, Bas J, Rodríguez-Moranta F, Serra K, Morandeira F, Colom H, Padullés N. **Predictors of infliximab trough concentrations in inflammatory bowel disease patients using a repeated-measures design.** Ther Drug Monit. 2020;42(1):102-110. PMID: [31283556](#).
32. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. **Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases.** Clin Gastroenterol Hepatol. 2019;17(9):1655-1668.e3. PMID: [30928454](#).
33. Martínez-Romero GJ, Alvariño A, Hinojosa E, Mora M, Oltra L, Maroto N, Ferrer I, Hinojosa MD, Hinojosa JE. **Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease.** Rev Esp Enferm Dig. 2019;111(6):431-436. PMID: [31021170](#).
34. Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo MG, Lourdes Setsuko Ayrizono M, Fagundes JJ, Leal RF. **Serum levels of infliximab and anti-infliximab antibodies in Brazilian patients with Crohn's disease.** Clinics (Sao Paulo). 2019;74:e824. PMID: [30994711](#).

35. Burgess CJ, Reilly C, Steward-Harrison L, Balouch F, Lewindon PJ. **Utility of proactive infliximab levels in paediatric Crohn's disease.** Arch Dis Child. 2019;104(3):251-255. PMID: [29950353](#).
36. Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R. **Drug levels in the maternal serum, cord blood and breast milk of a ustekinumap-treated patient with Crohn's disease.** J Crohns Colitis. 2019;13(2):267-269. PMID: [30388211](#).
37. Restellini S, Chao CY, Lakatos PL, Aruljothy A, Aziz H, Kherad O, Bitton A, Wild G, Afif W, Bessissow T. **Therapeutic drug monitoring guides the management of Crohn's patients with secondary loss of response to adalimumab.** Inflamm Bowel Dis. 2018;24(7):1531-1538. PMID: [29668893](#).
38. Fiorino G, Ruiz-Argüello MB, Maguregui A, Nagore D, Correale C, Radice S, Gilardi D, Allocca M, Furfaro F, Martínez A, Danese S. **Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease.** Inflamm Bowel Dis. 2018;24(3):601-606. PMID: [29462398](#).
39. Aguas Peris M, Bosó V, Navarro B, Marqués-Miñana MR, Bastida G, Beltrán B, Iborra M, Sáez-González E, Monte-Boquet E, Poveda-Andrés JL, Nos P. **Serum adalimumab levels predict successful remission and safe deintensification in inflammatory bowel disease patients in clinical practice.** Inflamm Bowel Dis. 2017;23(8):1454-1460. PMID: [28708805](#).
40. Marini JC, Sendeci J, Cornillie F, Popp JW Jr, Black S, Blank M, Gils A, Van Stappen T, Hamann D, Rispens T, Thérien L, Chun K, Shankar G. **Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade®.** AAPS J. 2017;19(1):161-171. PMID: [27600137](#).
41. Fiorino G, Correale C, Radice S, Allocca M, Furfaro F, Gilardi D, Nagore D, Del Rio L, Pascual J, Martínez A, Danese S. **Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.** Aliment Pharmacol Ther. 2017;46(9):903-905. PMID: [29023889](#).

RHEUMATOLOGY

1. Curry PDK, Hum RM, Morris AP, Jani M, Chinoy H, Barton A, Bluett J; for OUTPASS collaborators. **Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis.** *Rheumatology (Oxford)*. 2023;kead666. Epub ahead of print. PMID: [38070158](#).
2. Hum RM, Ho P, Nair N, Jani M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Plant D, Barton A; BRAGGSS Collaborators. **Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis.** *Rheumatology (Oxford)*. 2023;62(6):2090-2097. PMID: [36190343](#).
3. Meriño-Ibarra E, Manero Ruíz FJ. **Anti-TNF α drug levels in patients with rheumatoid arthritis and spondyloarthritis.** *Reumatol Clin (Engl Ed)*. 2022;18(8):475-479. PMID: [34953733](#).
4. Wong PKK, Bowling A, Bagga H, Giammichele D, Hobson P, Langguth D. **Serum trough levels of adalimumab correlate inversely with disease activity in patients with inflammatory arthritis.** *Joint Bone Spine*. 2021;88(4):105193. PMID: [33892195](#).
5. Tikhonova IA, Yang H, Bello S, Salmon A, Robinson S, Hemami MR, Dodman S, Kharechko A, Haigh RC, Jani M, McDonald TJ, Hoyle M. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. *Health Technol Assess*. 2021;25(8):1-248. PMID: [33555998](#).
6. Pedersen L, Szecsi PB, Johansen PB, Bjerrum PJ. **Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: data from a retrospective single-center cohort study.** *Biologics*. 2020;14:115-125. PMID: [33162753](#).
7. Mahmoud I, Rouached L, Ben Tekaya A, Saidane O, Bouden S, Jradi S, Sfar I, Tekaya R, Ben Abdelghani K, Lakhoua Gorgi Y, Abdelmoula L. **Immunogenicity of antitumor necrosis factor therapy in patients with spondyloarthritis.** *Drug Metab Pers Ther*. 2020;/j/dmdi.ahead-of-print/dmdi-2020-0139/dmdi-2020-0139.xml. PMID: [33155988](#).
8. Bodio C, Grossi C, Pregnolato F, Favalli EG, Biggioggero M, Marchesoni A, Murgio A, Filippini M, Migliorini P, Caporali R, Pellerito R, Ciccia F, Sarzi-Puttini P, Perosa F, Paolazzi G, Hollan I, Bendtzen K, Meroni PL, Borghi MO. **Personalized medicine in rheumatoid arthritis: how immunogenicity impacts use of TNF inhibitors.** *Autoimmun Rev*. 2020;19(5):102509. PMID: [32173513](#).
9. Perry M, Abdullah A, Frleta M, MacDonald J, McGucken A. **The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis.** *Ther Adv Musculoskelet Dis*. 2020;12:1759720X20904850. PMID: [32095163](#).
10. Brunelli JB, Silva CA, Pasoto SG, Saa CGS, Kozu KT, Goldenstein-Schainberg C, Leon EP, Vendramini MBG, Fontoura N, Bonfa E, Aikawa NE. **Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.** *Clin Rheumatol*. 2020;39(2):515-521. PMID: [31707543](#).
11. Senabre Gallego JM, Rosas J, Marco-Mingot M, García-Gómez JA, Santos-Soler G, Salas-Heredia E, Pons-Bas A, Barber-Vallés X, Bernal-Vidal JA, Cano-Pérez C, García-Carrasco M, Flores-Pardo E; AIRE-MB

Group. **Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis.** *Rheumatol Int.* 2019;39(5):841-849. PMID: [30899987](#).

12. Redondo C, Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Nuño-Nuño L, Peiteado D, Villalba A, Jochems A, Pascual-Salcedo D, Balsa A. **Golimumab tapering strategy based on serum drug levels in patients with spondyloarthritis.** *Arthritis Rheumatol.* 2018;70(8):1356-1358. PMID: [29736972](#).
13. Rosas J, Martín-López M, Otón T, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Carmona L. **Practical aspects of biological trough levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis.** *Reumatol Clin.* 2020;16(5 Pt 2):378-385. PMID: [30385295](#).
14. Balsa A, Sanmartí R, Rosas J, Martín V, Cabezas A, Gómez S, Montoro M. **Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.** *Rheumatology (Oxford).* 2018;57(4):688-693. PMID: [29365183](#).
15. Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Jurado T, Kneepkens EL, Wolbink GJ, Martín S, Ruiz Del Agua A, Navarro R, Mezcua A, Jochems A, Peiteado D, Bonilla MG, Balsa A, Pascual-Salcedo D. **Optimal concentration range of golimumab in patients with axial spondyloarthritis.** *Clin Exp Rheumatol.* 2018;36(1):110-114. PMID: [28980904](#).
16. Martínez-Estupiñán L, Hernández-Flórez D, Janta I, Ovalles-Bonilla JG, Nieto JC, González-Fernández CM, Del Río T, Monteagudo I, López-Longo FJ, Naredo E, Valor L. **An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.** *Clin Exp Rheumatol.* 2018;36(1):88-93. PMID: [28850020](#).
17. Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC. **Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.** *Ann Rheum Dis.* 2017;76(6):1078-1085. PMID: [28007755](#).
18. Teresa J, Chamada PR, Ana MF, Victoria NC, Theo R, Annick V, Karien B, Eva-María O, Cristina D, Alejandro V, Diana P, Laura N, Maria-Gema B, Alejandro B, Dora PS. **Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients.** *Open Rheumatol J.* 2017;11:75-87. PMID: [28761564](#).
19. Rosas J, Llinares-Tello F, Senabre-Gallego JM, Barber-Vallés X, Santos-Soler G, Salas-Heredia E, Pons Bas A, Cano Pérez C, García-Carrasco M; and the AIRE-MB Group. **Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis.** *Clin Exp Rheumatol.* 2017;35(1):145-148. PMID: [27908311](#).
20. Chen DY, Chen YM, Hsieh TY, Hung WT, Hsieh CW, Chen HH, Tang KT, Lan JL. **Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.** *Rheumatology (Oxford).* 2016;55(1):143-148. PMID: [26324949](#).
21. Plasencia C, Wolbink G, Krieckaert CL, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuño L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispen T, Pascual-Salcedo D, Balsa A. **Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.** *Clin Exp Rheumatol.* 2016;34(4):655-662. PMID: [27214767](#).
22. Almirall M, Gimeno R, Salman-Monte TC, Iniesta S, Lisbona MP, Maymó J. **Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy.** *Rheumatol Int.* 2016;36(4):575-578. PMID: [26815206](#).

23. Ghia C, Akerkar S, Sabnis S, Rao U, Rambhad G. **Analytical and clinical evaluation of an immunoassay for estimating immunogenicity of infliximab and etanercept in Indian population.** J Assoc Physicians India. 2016;64(9):14-17. PMID: [27762509](#).
24. Chimenti MS, Triggianese P, Narcisi A, Marinari B, Teoli M, Faleri S, Arcese A, Perricone R, Costanzo A. **Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response.** J Int Med Res. 2016;44(1 suppl):48-52. PMID: [27683139](#).
25. Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, Plasencia C, Balsa A, Llinares-Tello F, Rosas J, Torres N, Martínez A, Nagore D. **Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.** Ann Rheum Dis. 2016;75(9):1693-1696. PMID: [26965981](#)
26. Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R. **Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.** Arthritis Res Ther. 2016;18(1):160. PMID: [27391315](#).
27. Gupta R, Misra R. **Measuring anti-drug antibodies: a step towards optimization of biologic therapy.** J Assoc Physicians India. 2016;64(9):11-12. PMID: [27762508](#).
28. Chen DY, Chen YM. **Response to: ‘Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study’ by Sanmarti et al.** Ann Rheum Dis. 2015;74(8):e43. PMID: [25841164](#).
29. Sanmarti R, Inciarte-Mundo J, Estrada-Alarcon P, Garcia-Manrique M, Narvaez J, Rodriguez-Moreno J, Gomez-Centeno A, Pascal M, Yagüe J. **Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study.** Ann Rheum Dis. 2015;74(8):e42. PMID: [25805737](#).
30. Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Morgan AW, Wilson AG, Hyrich KL, Isaacs J, Barton A. **Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis.** Lancet. 2015;385(Suppl 1):S48. PMID: [26312870](#).
31. Chen DY, Chen YM, Hung WT, Chen HH, Hsieh CW, Chen YH, Huang WN, Hsieh TY. **Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment.** Ann Rheum Dis. 2015;74(12):2261-2264. PMID: [26443609](#).
32. Llinares-Tello F, Rosas-Gómez de Salazar J, Senabre-Gallego JM, Santos-Soler G, Santos-Ramírez C, Salas-Heredia E, Molina-García J; AIRE-MB Group. **Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of etanercept.** Clin Chem Lab Med. 2015;53(10):e279-e282. PMID: [26021413](#).
33. Valor L, Hernández-Flórez D, de la Torre I, Del Río T, Nieto JC, González C, López-Longo FJ, Monteagudo I, Llinares F, Rosas J, Garrido J, Naredo E, Carreño L. **Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients.** Clin Exp Rheumatol. 2015;33(6):805-811. PMID: [26314759](#).
34. Martín S, del Agua AR, Torres N, Pascual-Salcedo D, Plasencia C, Ruiz-Argüello B, Martínez A, Navarro R, Nagore D. **Comparison study of two commercially available methods for the determination of goli-**

mumab and anti-golimumab antibody levels in patients with rheumatic diseases. Clin Chem Lab Med. 2015;33(11):e297-e299. PMID: [25945722](#).

35. Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O. **Prevalence of TNF- α blocker immunogenicity in psoriatic arthritis.** J Rheumatol. 2015;42(1):73-78. PMID: [25399390](#).
36. Arstikyte I, Kapleryte G, Butrimiene I, Venalis A. **Influence of immunogenicity on the efficacy of long-term treatment with TNF α blockers in rheumatoid arthritis and spondyloarthritis patients.** Biomed Res Int. 2015;2015:604872. PMID: [26064930](#).
37. Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators. **Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of anti-drug antibodies on the long-term treatment response in rheumatoid arthritis.** Arthritis Rheumatol. 2015;67(8):2011-2019. PMID: [26109489](#).
38. Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, Hung WT, Lan JL. **Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.** Ann Rheum Dis. 2015;74(3):e16. PMID: [24442879](#).
39. Bandrés Ciga S, Salvatierra J, López-Sidro M, García-Sánchez A, Durán R, Vives F, Raya-Álvarez E. **An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.** J Clin Rheumatol. 2015;21(3):115-119. PMID: [25807089](#).
40. Rosas J, Llinares-Tello F, de la Torre I, Santos-Ramírez C, Senabre-Gallego JM, Valor L, Barber-Vallés X, Hernández-Flórez D, Santos-Soler G, Salas-Heredia E, Carreño L; AIRE-MB Group. **Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice.** Clin Exp Rheumatol. 2014;32(6):942-948. PMID: [25327159](#).
41. Mazilu D, Opreș D, Gainaru C, Iliuta M, Apetrei N, Luca G, Borangiu A, Gudu T, Peltea A, Groseanu L, Constantinescu C, Saulescu I, Bojinca V, Balanescu A, Predeteanu D, Ionescu R. **Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.** Biomed Res Int. 2014;2014:702701. PMID: [24982902](#).
42. Zamora-Atenza C, Diaz-Torne C, Geli C, Diaz-Lopez C, Ortiz MA, Moya P, Castellví I, Nieto JC, Cantó E, Casademont J, Juarez C, Llobet JM, Vidal S. **Adalimumab regulates intracellular TNF α production in patients with rheumatoid arthritis.** Arthritis Res Ther. 2014;16(4):R153. PMID: [25037855](#).
43. Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, Díez J, Nagore D, del Agua AR, Moral R, Martín-Mola E, Balsa A. **Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.** Ann Rheum Dis. 2012;71(12):1955-1960. PMID: [22563028](#).
44. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A. **Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.** Rheumatology (Oxford). 2011;50(8):1445-1452. PMID: [21427177](#).

1. Dodero-Anillo JM, Lozano-Cuadra IC, Rios-Sanchez E, Pedrosa-Martinez MJ, Ruiz-Carrascosa JC, Galan-Gutierrez M, Armario-Hita JC. **Optimising the therapeutic interval for biologics in patients with psoriasis.** *Life (Basel)*. 2022;12(12):2075. PMID: [36556440](#).
2. Elberdín L, Fernández-Torres RM, Mateos M, Outeda M, Blanco E, Gómez-Besteiro MI, Martín-Heranz I, Fonseca E. **Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis.** *Front Med (Lausanne)*. 2022;9:1017323. PMID: [36569163](#).
3. Sáez Belló M, Climente Martí M, Llopis Salvia P, Santos Alarcón S, Frias Ruiz P, Mateu Puchades A. **Monitorización farmacocinética de adalimumab como marcador precoz de fallo secundario en los pacientes con psoriasis en placa moderada-grave [Adalimumab therapeutic drug monitoring as early marker of secondary failure in patients with moderate-severe plaque psoriasis].** *Piel*. 2022;37(8):449-454. Article in Spanish. <https://doi.org/10.1016/j.piel.2021.10.012>.
4. Abdalla T, Mansour M, Bouazzi D, Lowes MA, Jemec GBE, Alavi A. **Therapeutic drug monitoring in patients with suboptimal response to adalimumab for hidradenitis suppurativa: a retrospective case series.** *Am J Clin Dermatol*. 2021;22(2):275-283. PMID: [33242185](#).
5. Martín-González S, Urigoitia-Ugalde P, Careaga J, Nagore D, Navarro R, Izu-Belloso R, Blanch L, González Del Tánago J, Martínez A, Ruiz Del Agua A. **Optimal concentration range of ustekinumab in patients with plaque-type psoriasis.** *J Am Acad Dermatol*. 2019;80(6):1782-1784. PMID: [30578816](#).
6. Colls-Gonzalez M, Notario-Rosa J, Bas-Minguet J, Padullés-Zamora A, Morandeira-Rego F, Valentí-Medina F, Colom-Codina H, Padullés-Zamora N. **Association between infliximab concentrations and clinical response in psoriasis: a prospective cohort study.** *J Dermatolog Treat*. 2021;32(2):180-187. PMID: [31696747](#).
7. Manriquez J, Alsina-Gibert M. **Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.** *Clin Exp Dermatol*. 2017;42(1):14-20. PMID: [27943384](#).
8. Ara-Martín M, Pinto PH, Pascual-Salcedo D. **Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.** *J Dermatolog Treat*. 2017;28(7):606-612. PMID: [28274164](#).
9. Elberdín L, Outeda M, Salvador P, Paradela S, Fernández-Torres RM, Iglesias R, Fonseca E, Martín I. **Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.** *Int J Clin Pharm*. 2016;38(5):1142-1148. PMID: [27436193](#).
10. Elberdín L, Outeda M, Salvador P, Paradela S, Fernández-Torres RM, Iglesias R, Fonseca E, Martín I. **Infliximab drug and antibody levels in patients with dermatological conditions.** *Int J Clin Pharm*. 2015;37(2):320-326. PMID: [25612566](#).
11. Marinari B, Botti E, Bavetta M, Spallone G, Zangrilli A, Talamonti M, Richetta A, Chimenti S, Costanzo A. **Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.** *Drug Dev Res*. 2014;75(Suppl 1):S11-S14. PMID: [25381966](#).

OPHTHALMOLOGY

1. Sejournet L, Kerever S, Mathis T, Kodjikian L, Jamilloux Y, Seve P. **Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study.** Br J Ophthalmol. 2022;106(10):1380-1386. PMID: [33875451](#).
2. Cordero-Coma M, Calleja-Antolín S, Garzo-García I, Nuñez-Garnés AM, Álvarez-Castro C, Franco-Benito M, Ruiz de Morales JG. **Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies.** Ophthalmology. 2016;123(12):2618-2625. PMID: [27692527](#).

COST-EFFECTIVENESS

1. Gómez-Arango C, Gorostiza I, Úcar E, García-Vivar ML, Pérez CE, De Dios JR, Alvarez B, Ruibal-Escribano A, Stoye C, Vasques M, Belzunegui J, Escobar A, Tranco Z, Ruiz Del Agua A, Del Rio L, Jorquera C, Diez E, Martínez A, Nagore D. **Cost-effectiveness of therapeutic drug monitoring-guided adalimumab therapy in rheumatic diseases: a prospective, pragmatic trial.** *Rheumatol Ther.* 2021;8(3):1323-1339. PMID: [34278555](#).
2. Laine J, Jokiranta TS, Eklund KK, Väkeväinen M, Puolakka K. **Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF- α blockers.** *Biologics.* 2016;10:67-73. PMID: [27099470](#).
3. Jani M, Gavan S, Chinoy H, Dixon WG, Harrison B, Moran A, Barton A, Payne K. **A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice.** *Rheumatology (Oxford).* 2016;55(12):2131-2137. PMID: [27576368](#).
4. Freeman K, Connock M, Auguste P, Taylor-Phillips S, Mistry H, Shyangdan D, Court R, Arasaradnam R, Sutcliffe P, Clarke A. **Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF- α) inhibitors [LISA-TRACKER[®] enzyme-linked immunosorbent assay (ELISA) kits, TNF- α -Blocker ELISA kits and Promonitor[®] ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.** *Health Technol Assess.* 2016;20(83):1-288. PMID: [27845027](#).

IMMUNOGENICITY

1. Vultaggio A, Nencini F, Bormioli S, Dies L, Vivarelli E, Maggi E, Matucci A. **Desensitization modulates humoral and cellular immune response to infliximab in a patient with an immediate hypersensitivity reaction.** J Allergy Clin Immunol Pract. 2020;8(5):1764-1767.e1. PMID: [31945487](#).
2. Pratesi S, Nencini F, Grosso F, Dies L, Bormioli S, Cammelli D, Maggi E, Matucci A, Vultaggio A; ABIRISK Consortium. **T cell response to infliximab in exposed patients: a longitudinal analysis.** Front Immunol. 2019;9:3113. PMID: [30687319](#).
3. Vultaggio A, Nencini F, Carraresi A, Pratesi S, Movérare R, Eriksson C, Venemalm L, Maggi E, Matucci A. **IgG4 anti-infliximab in treated patients: clinical impact and temporal evolution.** Allergy. 2018;73(11):2172-2181. PMID: [29719053](#).
4. Nencini F, Vultaggio A, Pratesi S, Cammelli D, Milla M, Fiori G, Bagnoli S, Prignano F, Romagnani S, Maggi E, Matucci A. **The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders.** J Allergy Clin Immunol Pract. 2018;6(6):2065-2072.e2. PMID: [29660428](#).

GENETICS

1. Salvador-Martín S, Pujol-Muncunill G, Bossacoma F, Navas-López VM, Gallego-Fernández C, Segarra O, Clemente S, Muñoz-Codoceo R, Viada J, Magallares L, Martínez-Ojinaga E, Moreno-Álvarez A, Sollar-Boga A, Loverdos I, Merino-Bohórquez V, Balboa-Vega MJ, Rodríguez-Martínez A, Álvarez-Vayo C, Sanchez C, Tolin M, Blanca-García JA, García-Romero R, Eizaguirre FJ, Sánchez-Hernández JG, de Caldas RG, Millán-Jimenez A, Aznal E, Abarca-Zabalía J, Sanjurjo-Sáez M, López-Fernández LA. **Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease.** Br J Clin Pharmacol. 2021;87(2):447-457. PMID: [32478906](#).
2. Aterido A, Palau N, Domènech E, Nos Mateu P, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Chaparro M, Panés J, García-Sánchez V, López-Lasanta M, Pluma A, Codó L, García-Montero A, Manyé J, Gisbert JP, Marsal S, Julià A. **Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease.** Pharmacogenomics J. 2019;19(6):547-555. PMID: [31043678](#).
3. Salvador-Martín S, López-Cauce B, Nuñez O, Laserna-Mendieta EJ, García MI, Lobato E, Abarca-Zabalía J, Sanjurjo-Saez M, Lucendo AJ, Marín-Jiménez I, Menchén LA, López-Fernández LA. **Genetic predictors of long-term response and trough levels of infliximab in Crohn's disease.** Pharmacol Res. 2019;149:104478. PMID: [31605784](#).

WHO INTERNATIONAL STANDARDS

1. Wadhwa M, Bird C, Atkinson E, Cludts I, Rigsby P. **The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring.** Front Immunol. 2021;12:636420. PMID: [33936049](#).
2. Metcalfe C, Dougall T, Bird C, Rigsby P, Behr-Gross ME, Wadhwa M, Study POT. **The first World Health Organization international standard for infliximab products: a step towards maintaining harmonized biological activity.** MAbs. 2019;11(1):13-25. PMID: [30395763](#).

